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Phenotypic Heterogeneity in
Hidradenitis Suppurativa (Acne Inversa):
Classification Is an Essential Step
Toward Personalized Therapy
John R. Ingram1 and Vincent Piguet1
Awareness is increasing that there is phenotypic heterogeneity within the
hidradenitis suppurativa (HS) disease spectrum. However, the few randomized
HS trials that are available have not distinguished between the subtypes of the
disease. In this issue, Canoui-Poitrine et al. used latent class (LC) analysis of the
largest HS cohort described to date to generate three phenotypic subtypes. LC 1
correlates with ‘‘typical’’ European HS, mainly involving the axilla, groin, and, in
women, the inframammary region. ‘‘Atypical’’ HS, which may be linked to
c-secretase gene mutations, was subdivided further into LC2 and LC3 subtypes.
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A model for how HS might be sub-
divided may be found in recent experi-
ences of investigators in characterizing
psoriasis. In fact, not all psoriasis is the
same; we now recognize several distinct
subtypes, based on clinical phenotype,
demographics, genetic predisposition,
and response to treatment. For example,
guttate psoriasis is composed of multiple
small plaques on the trunk of young
people of the HLA Cw0602 genotype,
and it commonly responds well to
phototherapy. Personalized medicine
projects are now in progress to match
more precisely psoriasis genotypes with
clinical phenotypes and treatment
responses, including the pharmacoge-
netics of systemic therapy.
HS (also known as acne inversa)
research is running to catch up, and
increasing awareness indicates that
there is phenotypic heterogeneity within
the disease spectrum. Common to all
HS patients are recurrent, painful
nodules, papules, and/or abscesses of
apocrine gland-bearing sites, in particular
the groin and axilla. ‘‘Typical’’ European
HS patients have lesions that are
restricted largely to these sites, but ‘‘aty-
pical’’ HS includes lesions that are more
widespread. In this issue, Canoui-Poitrine
et al. (2013) have provided a helpful step
by meticulously phenotyping 648 patients
with HS. LC analysis, with no a priori
hypotheses, was used to subdivide the HS
clinical phenotype into three groups,
based on affected skin sites, lesion types,
family history, and associations with
(severe) acne. ‘‘Axillary-mammary’’ (LC1)
HS corresponded to the ‘‘typical’’ pheno-
type seen in European populations. ‘‘Folli-
cular’’ (LC2) HS was characterized by
comedones, other follicular lesions, and
severe acne, whereas the ‘‘gluteal’’ (LC3)
HS had a predilection for the buttocks.
Utility of the proposed classification
The study by Canoui-Poitrine et al.
(2013) has several strengths, including
the large size of the patient population
and very little missing data. External
generalizations are probably limited to
See related article on pg 1506 European secondary-care centers
because of the recruitment of patients
from specialist clinics. Reasonable face
validity was confirmed by clustering of
the associated demographic data such
that, compared with the ‘‘axillary–
mammary’’ class, ‘‘follicular’’ patients
were more likely to be male, current
smokers, and have more severe disease.
A number of the demographic associa-
tions fit with preexisting observations,
for example, males were less likely to
have inframammary disease. As the
authors point out, validation studies
using other patient populations are
now needed.
Nomenclature has been a difficult
problem in HS research, exemplified
by the lack of universal agreement
regarding the condition’s name and
disease definition. Division of HS into
a ‘‘typical’’ European ‘‘axillary–mam-
mary’’ phenotype, with disease restricted
to axillary, inframammary, and groin
flexural sites, and an ‘‘atypical’’ group
provides a relatively clear distinction on
the basis of whether nonflexural sites are
involved. There will probably be some
debate regarding the subclassification of
the atypical group into ‘‘follicular’’ and
‘‘gluteal’’. In particular, the conditional
probability of gluteal involvement was
only 54% in the ‘‘gluteal’’ group, mean-
ing that half of this group did not have
gluteal involvement. Furthermore, one-
third of the ‘‘follicular’’ group did exhibit
gluteal involvement. In this context, it
may be prudent to consider renaming
the ‘‘gluteal’’ phenotype. One option
would be to focus on absent features.
For example, the ‘‘gluteal’’ group lacked
hypertrophic scars and epidermal cysts.
Genotype–phenotype correlation
The data provided by Canoui-Poitrine
et al. (2013) confirm that about one-
third of HS patients report a family
history of the condition. An autosomal
dominant pattern of inheritance was
reported 25 years ago, and, in 2010, a
Chinese group demonstrated underlying
pathogenic mutations in NCSTN, one of
the six genes encoding the g-secretase
transmembrane complex (Wang et al.,
2010). The Han Chinese HS patients
concerned were members of six fami-
lies with a relatively severe HS pheno-
type, including extensive involvement
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Table 1. Correlation between HS patient characteristics (phenotype) and c-secretase gene mutations
Patient characteristics
Study and
country of
origin
Family/
individual Affected sites Lesion types Other info
Phenotype
match Mutation
Wang et al.
(2010), China
Family 1 Not stated Not stated Proband had axillary SCC, FHx — PSENEN frameshift
Family 2 Axillae, groin, gluteal, back,
posterior neck
Hypertrophic scars FHx LC2 PSENEN frameshift
Family 3 Prominent—gluteal, back, chest,
face, posterior neck, waist
Mild—axillary
Hypertrophic scars FHx LC2 NCSTN frameshift
Family 4 Prominent—axillae, groin, gluteal
Mild—back, face, posterior neck,
waist
Proband folliculitis of elbows and
knees
Hypertrophic scars, folliculitis
(proband)
FHx LC2 PSEN1 frameshift
Family 5 Prominent—gluteal, back, chest,
face, posterior neck, waist
Mild—axillary
Hypertrophic scars FHx LC2 NCSTN altered
splicing
Family 6 Prominent—gluteal, back, chest,
face, posterior neck, waist
Mild—axillary
Hypertrophic scars FHx LC2 NCSTN nonsense
Pink et al.
(2011), UK
Patient 1 Axillae, breast, groin Comedones Caucasian, female, BMI 33, never
smoker, FHx
LC21 PSENEN frameshift
Patient 2 Axillae, breast, groin
gluteal
Hypertrophic scars, sinus tracts Caucasian, female, BMI 23, never
smoker, severe disease, FHx
LC2 PSENEN frameshift
Patient 3 Axillae, suprapubic, groin, gluteal,
thighs, neck
Sinus tracts, probably
hypertrophic scars
Caucasian, male, BMI 30, current
smoker, FHx
Atypical,
probably LC2
NCSTN altered
splicing
Liu et al. (2011),
China
Family 1 Axillae, gluteal, scalp, face, neck,
trunk, groin, limbs
Hypertrophic scars FHx LC2 NCSTN altered
splicing
Family 2 Back, abdomen, breast, gluteal Hypertrophic scars FHx LC2 NCSTN frameshift
Li et al. (2011),
China
Patient 1 Axillae, posterior neck, groin,
gluteal
Hypertrophic scars, inflamed
papules
Male, 21 year duration, onset age
26, FHx
LC2 NCSTN nonsense
Patient 2 Posterior neck, axillae, gluteal Inflamed papules, open
comedones
Female, 3 year duration, onset age
15, FHx
LC2 NCSTN nonsense
Patient 3 Axillae, groin, chest, back, gluteal,
posterior neck
Hypertrophic scars Male, 10 year duration, onset age
38, no FHx
LC2 NCSTN missense
Zhang et al.
(2012), China
Family 1 Axillae, posterior neck, groin,
gluteal
Hypertrophic scars, inflamed
papules
FHx LC2 NCSTN missense
Family 2 Face, posterior neck, genital Hypertrophic scars, inflamed
papules, cysts
FHx LC2 NCSTN missense
Pink et al.
(2012), UK
Patient 1 Axillae, breast, groin, gluteal Hypertrophic scars, sinus tracts Caucasian, female, BMI 38,
current smoker, no FHx, T2DM
LC2 NCSTN missense
Patient 2 Axillae, groin, gluteal Hypertrophic scars, sinus tracts Caucasian, female, BMI 37,
current smoker, no FHx, T2DM
LC2 NCSTN altered
splicing
Miskinyte et al.
(2012), France
Family 1 Axillae, groin, perianal Hypertrophic scars, fistulae FHx, severe disease, associated
acne conglobata
LC2 NCSTN nonsense
Family 2 Axillae, groin, perianal, gluteal Hypertrophic scars, fistulae FHx, associated acne conglobata LC2 NCSTN frameshift
Family 3 Axillae, groin, perianal Hypertrophic scars FHx, sacroiliitis in two individuals
and Crohn’s disease in one
LC2 NCSTN altered
splicing
Nomura et al.
(2012), Japan
Patient 1 Posterior neck, groin, genital, back Hypertrophic scars, fistulae Female, FHx LC2 NCSTN altered
splicing
Patient 2 Posterior neck, (also lesions in
typical flexural sites)
Comedones Male, FHx, mild disease LC2 NCSTN altered
splicing
Abbreviations: BMI, body mass index; FHx, family history of hidradenitis suppurativa; SCC, squamous cell carcinoma; T2DM, type 2 diabetes mellitus.
Phenotypic data are reproduced from descriptions and photographs included in genetic studies of individuals or families with hidradenitis suppurativa.
1The presence of comedones suggests LC2 rather than LC1 phenotype.
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of nonflexural skin regions. Since then,
loss-of-function g-secretase mutations
have been identified in British, French,
Japanese, and other Chinese HS patients
(Li et al., 2011; Liu et al., 2011; Pink
et al., 2011, 2012; Miskinyte et al.,
2012; Nomura et al., 2012; Zhang
et al., 2012). However, none of the 20
consecutive HS patients seen in a
tertiary UK setting were found to have
pathogenic g-secretase mutations, inclu-
ding 12 patients who reported a family
history of HS (Ingram et al., 2012). It is
possible that unrecognized mutations in
genes further down the g-secretase-
Notch signaling pathway may be
responsible (Melnik and Plewig, 2012).
One of the potential applications of the
phenotypic HS subtypes generated by
Canoui-Poitrine et al. (2013) is in the
field of genotype–phenotype correlation.
It is difficult to correlate individual g-
secretase mutations with the correspond-
ing phenotypic subtype because of a lack
of complete phenotypic data in many
reports. Nevertheless, Table 1 summarizes
the available phenotypic information, in
some cases relying in part on interpreta-
tions from clinical photographs, and it
details the corresponding g-secretase
mutation. All of the mutations appear to
correlate with atypical HS, and most are
probably best placed in the LC2 ‘‘follicu-
lar’’ subgroup, because of the involve-
ment of atypical body sites and the
presence of hypertrophic scarring. Of
the 20 HS patients without pathogenic
g-secretase mutations, the majority had a
‘‘typical’’ HS phenotype, and probably
only three exhibited features of the ‘‘folli-
cular’’ subgroup (Ingram et al., 2012).
Minimum HS phenotype data set?
Difficulties encountered when trying to
determine the phenotypic subgroups of
HS patients in genetic studies reinforce
the need for a minimum HS phenotype
data set for future studies. This would be
best determined through formal ‘‘consen-
sus’’ methods, but one suggestion can be
found in Table 2. Nearly all of these
elements were included in the study by
Canoui-Poitrine et al. (2013), except for a
patient-reported disease severity measure
in the form of quality of life scores.
Translational value for clinical practice
For patients, perhaps the most important
element of a classification system would
be its predictive validity. Obviously, it is
not yet known whether using the pro-
posed system to stratify clinical trials
would help to distinguish responders
from nonresponders to a specific treat-
ment modality. Another important unan-
swered question would be whether
there are phenotypic predictors of
severe disease that might justify early
treatment to arrest disease progression
and to prevent subsequent scarring and
reduced quality of life.
The focus on accurate HS pheno-
typing provided by Canoui-Poitrine
et al. (2013) is an essential step in
determining potential genotype–pheno-
type correlations within the HS disease
spectrum, and it permits a better under-
standing of HS etiology. For patients,
ultimately, it may allow a more perso-
nalized approach to therapy.
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Clinical Implications
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 Latent class (LC) analysis of a European patient population was used to
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Table 2. Suggested minimum HS phenotype data set
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Associated
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Affected regions Axillae, groin, gluteal, inframammary, posterior neck/ears, trunk, limbs, other
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Patient reported—validated quality of life measure
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treatment
Topical/systemic/surgical/other
Abbreviations: BMI, body mass index; HS, hidradenitis suppurativa.
1From Sartorius et al. (2009).
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Cutaneous Human Papillomavirus
Infection and Basal Cell Carcinoma
of the Skin
Mina S. Ally1, Jean Y. Tang1 and Sarah T. Arron2
Human papillomavirus (HPV) is ubiquitous in skin and has been associated with
nonmelanoma skin cancer. Iannacone et al. investigate the role of HPV in basal
cell carcinoma (BCC) by assessing the presence of HPV antibodies, HPV DNA in
tumors, and the relationship between these two markers and BCC. In contrast to
squamous cell carcinoma (SCC), there is no association between HPV and BCC.
Journal of Investigative Dermatology (2013) 133, 1456–1458. doi:10.1038/jid.2013.46
UV radiation is the most important risk
factor for nonmelanoma skin cancers
(NMSCs). However, in the past decade,
evidence has implicated human papil-
lomavirus (HPV) as a possible risk factor
in their development. Ascertaining the
role of cutaneous HPV infection in
NMSCs is important, especially as cer-
tain genera of HPV are believed to
augment UV radiation–induced DNA
damage (Arron et al., 2011).
HPV is a DNA virus that replicates
exclusively in keratinocytes and relies
on the differentiation of keratinocytes to
complete its life cycle (Aldabagh et al.,
2012). There are over 180 types of HPV,
which have specific tropism for
cutaneous or mucosal epithelium, and
belong to one of five genera: alpha,
beta, gamma, mu, or nu. The
association between high-risk alpha-
HPV and cervical cancer and the
mechanism for viral transformation
have been well established, but
associations reported between HPV
and NMSC are inconsistent.
In this issue, Iannacone et al. (2013)
address the question of whether HPV is
associated with the development of
basal cell carcinoma (BCC). They
evaluated circulating antiviral antibodies
and lesional HPV DNA, and determined
that there is no association between this
virus and BCC.
See related article on pg 1512
HPV and NMSC
Several groups have reported the pre-
sence of HPV DNA in lesional tissue
and antibody seropositivity to cutaneous
HPV, especially beta types, in patients
with squamous cell carcinoma
(SCC; Bouwes Bavinck et al., 2010;
Aldabagh et al., 2012). Both HPV
carriage and SCC, but not BCC, are
increased in immunosuppressed indi-
viduals, suggesting an etiological role
for this virus in SCC. At present, there
are only a few conflicting studies on the
role of HPV in BCC.
No study to date has found a signifi-
cant association between seropositivity
to any genus-beta type and BCC
(Feltkamp et al., 2003; Andersson
et al., 2008; Karagas et al., 2010); two
studies failed to show an association
with genus-alpha seropositivity as well
(Andersson et al., 2008, 2012). One
report found that patients with BCC
had lower seroprevalence than controls
with benign skin diagnoses, which was
postulated to be due to the inability of
patients with BCC to mount an adequate
HPV antibody response (Andersson
et al., 2008). To date, only two studies
have reported findings on the
association between BCC and
seroreactivity to cutaneous HPV in
genera other than the beta-genus
(Andersson et al., 2008, 2012).
In this issue, Iannacone et al. (2013)
investigate the association between BCC
and HPV in a US population, using a
clinic-based case–control study of 224
immunocompetent patients with BCC
and 300 controls. They report the ser-
oprevalence of antibodies to cutaneous
papillomaviridae from all five genera of
HPV and the presence of lesional viral
DNA in a subset of tumors. However,
there was no analysis of viral DNA from
tissue in control subjects for compari-
son. Serum antibodies investigated by
Iannacone et al. (2013) include those
against cutaneous alpha types 2, 3, 7,
10, 27, 57, and 77; beta types 5, 8, 9,
15, 17, 20, 23, 24, 36, 38, 49, 75, 76,
92, 96, and 107; gamma types 4, 48,
50, 65, 88, 95, 101, and 103; mu type
1; and nu type 41. The authors detected
viral DNA in lesional tissue from of beta
types 5, 8, 9, 12, 14, 15, 17, 19, 20, 21,
22, 23, 24, 25, 36, 37, 38, 47, 49, 75,
76, 80, 92, 93, and 96; gamma types 4,
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